期刊文献+

高效液相色谱法测定司坦夫定及其有关物质的含量

Determination of Stavudine and Related Substances by HPLC
下载PDF
导出
摘要 目的 :建立测定司坦夫定及其有关物质含量的高效液相色谱法。方法 :分析柱 :HypersilC18(4 6mm×150mm ,5μm) ;流动相 :甲醇 -水 (13∶87,V/V) ;检测波长 :264nm ;流速 :1ml/min ;柱温 :20℃。结果 :司坦夫定在0 025~0 3mg/ml范围内呈现良好的线性关系 (r=0 9999 ,n=6) ,平均回收率为99 26 % (RSD=0 76 % )。3批司坦夫定原料的百分含量依次为99 48 %、99 55 %和99 32 % ;3批司坦夫定自制胶囊和进口胶囊的百分标示量依次为97 21 %、101 54 %、98 92 %和100 57 %、97 86 %、102 33 %。结论 :本方法具有简便、准确、灵敏且重现性好的特点 ,可用于司坦夫定原料及其制剂的含量测定。 OBJECTIVE:To establish a HPLC method for the determination of stavudine and related substances METHODS:The Hypersil C18(4 6mm×150mm,5μm)was used as analysis column The mobile phase was methanol-water(13∶87,V/V) Detection wavelength was 264nm The flow rate was 1ml/min The column temperature was 20℃ RESULTS:The calibration curves was linear in the concentration range of 0 025~0 3mg/ml(r=0 9 999,n=6) The average recovery was 99 26%(RSD=0 76%) The contents of stavudine in 3 batches of semifinished materials and stavudine capsules(imported and domestic)were 99 48%,99 55%,99 32%(materials);97 21%,101 54%,98 92%(imported stavudine capsule);100 57%,97 86%,102 33%(domestic stavudine capsule)respectively CONCLUSION:The method is simple,accurate,sensitive and repeatable and it is suitable for the determination of stavudine and its preparations
出处 《中国药房》 CAS CSCD 2002年第7期428-429,共2页 China Pharmacy
关键词 司坦夫定 含量测定 高效液相色谱法 stavudine related substance content determination HPLC
  • 引文网络
  • 相关文献

参考文献10

  • 1[1]Gandhi RB, Bogardus JB, Bugay DE, et al.Pharmaceut- ical relationships of three solid state forms of stavudine [J].Int J Pharm, 2000, 201( 2) : 221.
  • 2[2]Gisolf EH, Van Heeswijk RP, Hoetelmans RW, et al.Decreased exposure to saquinavir in HIV- 1- infected patients after long- term antiretroviral therapy includi- ng ritonavir and saquinavir[J].AIDS, 2000, 14( 7) : 801.
  • 3[3]Paolucci S, Baldanti F, Maserati R, et al.Quantification of the impact of HIV- 1 reverse transcripatase and pr- otease mutations on the efficacy of rescue HAART[J].Antiviral Res, 2000, 45( 2) : 101.
  • 4[4]Elion R, Kaul S, Knupp C, et al.The safety profile and antiviral activity of the combination of stavudine, dida- nosine, and nelfinavir in patients with HIV infection[J].Clin Ther, 1999, 21( 11) : 1 853.
  • 5[5]Van Laethem K, Schmit JC, Pelemans H, et al.Presence of 2′,5′ - Bis- O - ( tert- butyldimethylsilyl) - 3′ - spiro- 5′ - ( 4′ - amino- 1′,2′ - oxath iole - 2′,2′ - dioxide) ( TS- AO) - resistant virus strains in TSAO- inexperienced H- IV patients[J].AIDS Res Hum Retroviruses, 2000, 16( 9) : 825.
  • 6[6]Losso MH, Belloso WH, Emery S, et al.A randomized, controlled, phase Ⅱ trial comparing escalating doses of subcutaneous interleukin- 2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus- infected patients[J].J Infect Dis, 2000, 181( 5) : 1 614.
  • 7[7]Gisolf EH, Jurriaans S, Pelgrom J, et al.The effect of tr- eatment intensification in HIV- infection: a study com- paring treatment with ritonavir/saquinavir and ritonav- ir/saquinavir/stavudine.Prometheus Study Group[J].AIDS,2000, 14( 4) : 405.
  • 8[8]Moyer TP, Temesgen Z, Enger R, et al.Drug monitori- ng of antiretroviral therapy for HIV- 1 infection: met- hod validation and results of a pilot study[J].Clin Chem, 1999, 45( 9) : 1 465.
  • 9[9]Solas C, Li YF, Xie MY, et al.Intracellular nucleotides of ( - ) - 2′,3′ - deoxy- 3′ - thiacytidine in peripheral blood mononuclear cells of a patient infected with hum- an immunodeficiency virus[J].Antimicrob Agents Che- mother, 1998, 42( 11) : 2 989.
  • 10[10]Meier C, Lorey M, De Clercq E, et al.CycloSal- 2′,3′ - dideoxy- 2′,3′ - didehydrothymidine monophosphate( cy- cloSal- d4TMP) : synthesis and antiviral evaluation of a new d4TMP delivery system[J].J Med Chem, 1998, 41 ( 9) : 1 417.

相关主题

;
使用帮助 返回顶部